Pharos IBio Co Ltd
388870
Company Profile
Business description
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.
Contact
427beon-gil, Dongan-gu
1407 and 1408, 38, Heungan-daero, Seongji Star With
Gyeonggi-do, Gwanyang-dong
Anyang-si
KORT: +82 313456170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
34
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,507.90 | 2.80 | -0.03% |
CAC 40 | 7,873.83 | 23.73 | 0.30% |
DAX 40 | 23,638.56 | 72.02 | 0.31% |
Dow JONES (US) | 42,140.43 | 269.67 | -0.64% |
FTSE 100 | 8,602.92 | 2.06 | -0.02% |
HKSE | 23,438.11 | 329.84 | 1.43% |
NASDAQ | 19,010.09 | 301.74 | 1.61% |
Nikkei 225 | 37,971.75 | 211.51 | -0.55% |
NZX 50 Index | 12,783.13 | 3.61 | -0.03% |
S&P 500 | 5,886.55 | 42.36 | 0.72% |
S&P/ASX 200 | 8,263.50 | 5.50 | -0.07% |
SSE Composite Index | 3,381.17 | 6.30 | 0.19% |